In this expert Q&A we are delighted to welcome our Editorial Board member Dr Sanjay Kalra, a leading endocrinologist with over two decades of experience at Bharti Hospital, Karnal, India. A passionate educator and researcher, Dr Kalra serves as Education Editor of the International Society of Endocrinology (ISE) and is deeply involved in global endocrine education. His leadership extends to roles such as Immediate Past President of the Endocrine Society of India and Vice-President of the South Asian Federation of Endocrine Societies.
Dapiglutide is a once-weekly, subcutaneous dual GLP-1/GLP-2 receptor agonist being investigated for the treatment of obesity. This first-in-class molecule is designed to take advantage of the weight-loss effects of GLP-1 agonist and the additional benefit of a GLP-2 agonist on improving intestinal barrier function and addressing co-morbidities associated with low-grade inflammation seen in obesity.
After yet another successful congress, who better to reflect on the highlights than the current EASD President, Prof. Chantal Mathieu? In this interview, we explore the packed agenda, discussing everything from the prestigious prize lectures to ground-breaking research.
We explore some of the most exciting data presented, including advancements in long-acting insulins, novel technologies and islet transplantation). We also touch on pivotal type 1 diabetes research (T1D), and a crucial call to action for addressing cardiovascular comorbidities in this patient population.
‘Closed-loop’ systems mark a significant advancement in managing type 1 diabetes. These systems which continuously monitor glucose levels and automatically deliver insulin through a pump, help many individuals with type 1 diabetes maintain optimal glucose levels with greater ease. In this episode, we explore the progress, challenges and impact of these innovative technologies with Endocrinology Clinical Pharmacy Specialist, Dr Diana Isaacs, and highlight their future potential.
Education, Conference Coverage and Articles
It is with great pleasure that we present this latest issue of touchREVIEWS in Endocrinology, which brings together a diverse array of high-quality articles focused on the evolving landscape of endocrine disorders. The importance of patient-centred care is exemplified in ...
This systematic review and meta-analysis investigate the efficacy of teprotumumab, a novel monoclonal antibody, in reducing proptosis for patients with long-duration thyroid eye disease (TED). While teprotumumab has shown promise in treating active TED, its effectiveness in chronic cases remained ...
Dry eye disease (DED) is known as dry eye syndrome (DES) or keratoconjunctivitis sicca. According to the Tear Film and Ocular Surface Society’s Dry Eye Workshop II (TFOS DEWS II), it constitutes a multifactorial disease of the ocular surface, ...
The prevalence of diabetes during pregnancy is rapidly increasing. In the USA alone, an estimated 1–2% of pregnant women have type 1 diabetes (T1D) or type 2 diabetes (T2D), and an additional 6–9% develop gestational diabetes.1 From 2000 to 2010, the prevalence of gestational ...
Share your knowledge, influence clinical practices and enhance patient care in Endocrinology today!
Hepatic steatosis is the liver manifestation of metabolic syndrome and a common cause of chronic liver disease. Nonalcoholic fatty liver disease (NAFLD) diagnosis relies on the presence of hepatic steatosis, defined as >5% fat accumulation in the liver, as observed ...
Hypercalcaemia is a common clinical condition in hospitalized patients. Malignancies and primary hyperparathyroidism (PHPT) are the two most common causes of hypercalcaemia in hospitalized patients.1–3 Apparently, there is a changing profile of hypercalcaemia in India, especially in hospital settings, because ...
Dipeptidyl peptidase-4 (DPP-4) is a ubiquitous, multifunctional, 766-amino acid, type 2 transmembrane glycoprotein, which participates in the regulation of metabolic functions, immune and inflammatory responses, cancer growth and cell adhesion.1Â It has two forms: the first is a membrane-bound form, which ...
Polycystic ovary syndrome (PCOS) is a multifactorial, multifaceted syndrome that affects women across all ages from adolescence to post-menopause. It is reported to be the most common endocrinopathy in women of the reproductive age group.1Â The nature of this syndrome ...
‘Closed-loop’ systems mark a significant advancement in managing type 1 diabetes. These systems which continuously monitor glucose levels and automatically deliver insulin through a pump, help many individuals with type 1 diabetes maintain optimal glucose levels with greater ease. In this episode, we explore the progress, challenges and impact of these innovative technologies with Endocrinology Clinical Pharmacy Specialist, Dr Diana Isaacs, and highlight their future potential.
Hyperthyroidism is prevalent in 0.1–2.5% of the population, and Graves’ disease is diagnosed in 80% of patients with hyperthyroidism.1,2 This condition arises from the uncontrolled, excessive activation of the thyroid-stimulating hormone (TSH) receptor by autoreactive TSH-receptor antibodies.2 Elevated thyroid hormones in hyperthyroidism ...
Thyroid nodules are common worldwide, and their prevalence is increasing. Most nodules are asymptomatic and detected incidentally on cross-sectional imaging or physical examination. In rare cases (10–15%), nodules are malignant and require diagnostic evaluation. Even malignant nodules frequently show non-aggressive behaviour.1 ...
Metformin Metformin has been recommended as the first-line glucose-lowering agent for the management of type 2 diabetes (T2D) for several decades due to its efficacy and safety profile.1–3 In fact, metformin has been widely used as an insulin-sensitizing agent for ...
Tirzepatide is a first-in-class novel dual glucose-dependent insulinotropic peptide (GIP)/glucagon-like peptide-1 (GLP-1) receptor agonist (twincretin), formulated as a synthetic peptide containing 39 amino acids based on the native GIP.1Â Tirzepatide has a GIP receptor-binding affinity comparable with native GIP and ...
Welcome to the latest edition of touchREVIEWS in Endocrinology, which features a range of review, case report and original research articles that highlight some key developments in our understanding and management of endocrinological disease. We begin with a commentary from ...
Type 2 diabetes (T2D) continues to pose an ever-greater global health challenge, with 1.31 billion individuals predicted to be living with diabetes globally by 2050; the majority of whom will have T2D.1Â Closely linked to T2D is metabolic dysfunction-associated steatotic ...
Cushing’s disease (CD) is caused by an adrenocorticotropic hormone (ACTH)-secreting pituitary adenoma, or rarely carcinoma, and is considered a highly morbid endocrine disorder with few medical options.1,2 Although transsphenoidal pituitary surgery (TSS) is the mainstay of treatment for ...
Watch leading experts Prof. Moshe Phillip, Dr Sandro Loche and Prof. Antonio de Arriba discuss challenges in growth hormone disease management, and how digital health tools and data analytics can support HCPs and improve outcomes for patients.
Introducing the Editorial Board of touchREVIEWS in Endocrinology, who support our mission to advance medical knowledge and practice by ensuring the integrity, relevance, and impact of the content we publish. Together, we strive to foster a vibrant academic community and contribute to the continuous improvement of healthcare worldwide.
Diabetes
Director, Diabetes Division and Clinical Research Center of Iatriko P. Falirou Medical Center, Athens, Greece
Dr John Doupis is a former clinical research fellow of the Joslin Diabetes Center, Harvard Medical School, in Boston, MA, USA and scientific partner in Beth Israel Deaconess Foot Center Harvard Medical School, Boston, MA. Currently, he is directing the Diabetes Division and Clinical Research Center of Iatriko P. Falirou Medical Center in Athens, Greece. He has served as a principal investigator in many multicentre phase I, II, III and IV clinical trials, most of which have been published in international journals or presented at congresses. He is a registered reviewer and a member of the editorial board for many major diabetes medical journals. He has given numerous lectures in national and international congresses, presenting over 200 abstracts. His special areas of interest are diabetes and its complications, especially obesity, diabetic neuropathy, diabetic foot, as well as the glucose sensing technologies and insulin pumps. In these fields, he has published more than 50 papers in international medical journals, having more than 1,500 citations.
Diabetes
Professor of Medicine at the Katholieke Universiteit and Chair of Endocrinology at the University Hospital Gasthuisberg Leuven, Belgium
Prof. Chantal Mathieu is a physician-scientist who has contributed to the field of diabetes and endocrinology through basic and clinical research. Her basic research work focuses on pathogenesis and prevention of type 1 diabetes. Prof. Mathieu’s clinical work involving new products and treatment paradigms in diabetes, such as new insulins, adjunct therapies and diagnosis of gestational diabetes have made her a speaker in international fora. Prof. Mathieu coordinates the European clinical trial network for interventions in type 1 diabetes ‘INNODIA’ and the European project ‘EDENT1FI’ on screening for type 1 diabetes. Prof. Mathieu is president of EASD and vice-president of the European Diabetes Forum.
Diabetes
Continuous Glucose Monitoring (CGM) Program Coordinator and Endocrinology Clinical Pharmacy Specialist, Cleveland Clinic Diabetes Center, Cleveland, OH , USA
Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES is the Continuous Glucose Monitoring (CGM) Program Coordinator and Endocrinology Clinical Pharmacy Specialist at the Cleveland Clinic Diabetes Center. She provides medication management and runs a robust CGM shared medical appointment program. Dr Isaacs is a Certified Diabetes Care and Education Specialist and holds board certifications in pharmacotherapy, ambulatory care and advanced diabetes management. She has numerous diabetes publications and research projects with a focus on medications, CGM and diabetes technology.
Diabetes
Emeritus Professor of Medicine and Professor of Nursing, Health and Community Systems at the University of Pittsburgh, PA, USA
Linda Siminerio, RN, PhD is Emeritus Professor of Medicine and Professor of Nursing, Health and Community Systems at the University of Pittsburgh. She has led a career in diabetes research and education. An internationally recognized expert on self-management education and health care delivery models in both pediatric and adult populations, she serves as the Principal Investigator on many studies related to diabetes treatment.
Dr Siminerio has authored numerous publications and served as editor on several diabetes journals. She was President of Health Care and Education, American Diabetes Association and Senior Vice President, International Diabetes Federation (IDF) and Past-Chair of the National Diabetes Education Program (NDEP). In these positions, she has organized and led national and international efforts on the development of programs, standards and care models directed toward health professionals, patients and the community.
Dr Siminerio served as organizing chair for the International Diabetes Federation (IDF) World Diabetes Congress and IDF translation research program, Building Research in Diabetes Global Environments and Systems (BRIDGES).
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.